Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It is advantageous when the sp has dropped half a penny in a week
It's very rare in situations like this that getting in before results is advantageous, or worth the risk.
Expect a major rise to 2p plus after.
Take your positions now
Indeed. If memory serves correct, even larger inside buys by one or more of the 4D Directors. Look what happened there.
Remind me, how many shares has the CEO bought here?
Regardless, watching with a degree of morbid curiosity to see how this plays out.
Clear expectations for what the ultimate conclusion is going to be of course, but maybe this time it will be different?
I can only imagine that is the basis for anyone taking a punt here right now. Like an unhealthy gambling habit, lol. Your money, your choice of course.
What's the "technical accountants " specialty?
Raising funds I believe.
What was the reason why the last CFO was let go/moved on?
Still on word on the 3rd party.
I've been incredibly bearish since the last results and saw good reason for the slump to 1.5p but there's no doubt that sub 1p is pretty good punt money for a lowball TO in the 2s later this year.
Are you sure?
Were dies your confidence come from?
Research "Connaught" thd new Big shot Boss bought £500k, 2 weeks later it went tits up 20,000 staff gone.
A lot of times directors buys can be very misleading. This is been played out over and over again. However I long for the 6p+ days to come...🙏🙏
London, UK, 27 November 2023: Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol), confirms that Mr Hans Peter Hasler, Chairman, acquired 2,000,000 Ordinary Shares in the Company on 21 November 2023 at a price of 6.1p per share. Mr Hasler now holds a beneficial interest in 5,500,000 Ordinary Shares.
THIS IS A BUY
The market has almost priced in the worst that can happen but it has not happened yet
At the current price, holding seems more sensible until we see more evidence of a sudden business downturn from the corrected position they have already declared.
There are many AIM companies in similar positions and if the sales are still growing at the stated rate and the new accountant has a grip on costs there will at some point be an SP recovery. (results next Tuesday)
This is oversold
Sales will go through the roof this year
Question: Why would Hans Peter Hasler buy £122k worth of shares at 6.0p back in November 2023 if this share is considered a burning platform with year end results due Tuesday?
ITS THERE CASH BURN HERE need more funds soon at what price ? Directors NOT EVEN BUYING I FEEL THE WORST HERE if great rns says its going great i buy yes have to pay a lot more but it be worth it
E_AL.....I await your buy, if you wait long enough you might even match AOP.
You forgot to mention the elephant in the room...lol
They missed their own revised target by a whopping 55-60k odd prescription and blamed someone else. It ain't that hard to count to 130,000.
How much of the 13m is burnt through already?
Optrade-
I love your optimistic view and I genuinely do hope you are 100% correct, but I doubt it. AOP will be waiting to lift the lot cheap before the enivatable happens.
LWHL,
like me is a realist. If it walks like a duck, quacks like - you know the rest.
GLA that have the ba**s or stupidity to hold.
Hopefully we survive and may come good at some point before dilution/fund raises kills us off.
You said a very similar thing back in early April, when the SP was 1.85p.
Maybe this time will be different, eh?
I suspect a few of us have our doubts, based on the history here.
But of course, that is what makes a market.
The asset is significantly oversold based on the daily and weekly technical charts and it's NT to buy at the moment. To me, it seems like this drop was a deliberate move to trigger any remaining stop losses before the results are announced. I will buy here and hold for the results
From the latest trading update:
Business Metrics:
· Cash: $13.9m as of 31 December 2023
· Total 2023 revenue and other income: $17.5m, a 2.8x increase over FY22
o Accrufer® revenue: $11.6m, a 3.1x increase over FY22
o Ex-U.S. revenue: $1.5m
o Other income revenue including Viatris milestone payments: $4.4m
· U.S. Q4 2023 Revenue: $4.3m
· Average net selling price: c.$145/prescription in H2 2023, an increase of c.21% compared with H1 2023
· Total 2023 Prescriptions: c.77k, a 3.1x increase over FY22
You have no proof of that Sym, it may have been a genuine misquote mistake that won't happen again.
There is no evidence the company is about to collapse.
The fear of complete annihilation has really taken hold and there seems nothing will stop it.
What's the outcome of this?
It's all very sad that inept people are allowed to run companies into the ground, even when they have a alleged wonderful product.
Yes the SP has slipped a lot not without reason, but put the misquote to one side and the results still looked quite good.
The big question here is what the results will look like on April 30th, they have a new experienced accountant and if the adjusted official figures are anything like what they have indicated you could expect a big bounce.
Worth at least holding or possibly adding at these very low levels.
For a company with a history of insider trading, when the share price continues to fall off a cliff it's all you need to know. Uncertainty isn't so much whether they'll crash the car, but how they'll do it. Imo it'll be covenant breach.
None at all are, to my knowledge, neon. That is why I said I was disappointed that it has not happened, given everything that has gone on here.
I think that there have simply been too many unusual happenings here, not just the recent misleading information concerning those prescription numbers, which in itself was very serious, and IMO warranted regulatory scrutiny for that alone. Especially as the BOD have not followed up with their allegations against that third party, which they should have notified the market of by now.
As someone who has lost money here, but who gave the company the support and benefit of the doubt for quite some time, the lack of any update since the last RNS is the cherry on top really.
But not investment advice of course. Draw your own conclusions from all the previous RNS material and interviews, the fund raises, some of the historic share price movements just before certain events and where the company now sits, as far as we are currently aware. Perhaps you will draw a different conclusion. GLA anyway. Except the BOD.
Sorry LWHL, who is under investigation and by whom? FCA? SFO? Is it the company or the directors or all of them?
Thanks for your kind opinion LWHL
Neon: in all probability, this is not in the hands of the shareholders anymore. Well, only one shareholder's hands, realistically, perhaps. IMO.
Amazed it has not been suspended and quite frankly disappointed that we have not been notified that they are under investigation, which IMO they absolutely should be.
Disregard for shareholders since the last update, on a scale that is as bad as I can remember. And that is saying something for AIM.
I hope they do not get another raise away to be honest. They have already drained far too much money in wages and other benefits for complete failure.
Unfortunately, they have probably earned enough here to no longer need to rely on future employment. I would not go near any listed outfit that took them on in future anyway.
But sunk cost fallacy is a strong emotion, so I am sure I will not get any of my desires here. GLA while we wait to see what new delights they have lined up for shareholders.
Question: how much they can raise say at 1.20p/1p for example before asking shareholders permission?
News probably got leaked somehow(!)